Sichenzia Ross Ference LLP Represents Lexaria Bioscience Corp. in Close of $11 Million Underwritten Public Offering and NASDAQ Uplisting

Press Release – New York, NY – January 14, 2021 – Sichenzia Ross Ference LLP announced today that it represented Lexaria Bioscience Corp. (NASDAQ: “LEXX”), in a closing of an underwritten public offering of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit. Lexaria uses proprietary drug delivery technology, DehydraTECH™, improving the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. The gross proceeds from the offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses.

The offering was made pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC).

H.C. Wainwright & Co. acted as the sole book-running manager for the Offering.

The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Avital Perlman, and associate Jacob Tabman and law clerk Zachary Weiss.

Author
Recent Posts

Sichenzia Ross Ference LLP

Sichenzia Ross Ference LLP is a full service law firm with a nationally recognized corporate, securities and litigation practice that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRF’s renowned litigation department specializes in defending companies and individuals against all types of securities cases, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations. The litigation team has also brought defamation lawsuits against companies and individuals related to market manipulation. Additionally, it represents individuals and companies in investigations by the Securities and Exchange Commission (SEC) and other regulatory bodies. The litigation team has a robust practice representing brokers and broker-dealers in arbitrations before the Financial Industry Regulatory Authority (FINRA). These arbitrations typically involve claims of unsuitability, churning, unauthorized trading and other allegations of broker misconduct. Finally, SRF has a burgeoning expungement practice, where it represents brokers seeking to have negative and harmful customer complaints removed from their industry records. The firm complements its core practice areas with an established commercial real estate and trusts and estates practice.

Visit SRF's LinkedIn page

Latest posts by Sichenzia Ross Ference LLP (see all)

Sichenzia Ross Ference LLP Announces Over 80 Capital Markets Transactions Valued Over $2 Billion at the Closing of 2021 - January 13, 2022
Sichenzia Ross Ference LLP Adds Two Key Additions to its Corporate and Securities Law Team - January 11, 2022
Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $9.8 Million Underwritten Offering of BiondVax Pharmaceuticals Ltd. - December 30, 2021

Sichenzia Ross Ference LLP Represents Lexaria Bioscience Corp. in Close of $11 Million Underwritten Public Offering and NASDAQ Uplisting

Related Posts